Abstract
Rheumatoid arthritis (RA) is a chronic, autoimmune, inflammatory disease of the joints that affects subjects of all ages, with a predilection for women of postmenopausal age. Although the etiology of RA is still unknown, its pathogenesis is the result of multiple factors acting against the background of genetic predisposition. Inflammation is probably triggered by nonspecific and as yet unknown infectious agents. The course of RA is usually chronic with alternating periods of exacerbation and abatement. RA is not necessarily confined to the joints but can cause extraarticular manifestations that are frequently severe and sometimes life-threatening.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aho K, Heliövaara M, Maatela J, Tuomi T, Palosuo T. Rheumatoid factors antedating clinical rheumatoid arthritis. J Rheumatol 1991; 18: 1282–4.
Aho K, Kaipiainen-Seppänen O, Heliövaara M, Klaukka T. Epidemiology of rheumatoid arthritis in Finland. Semin Arthritis Rheum 1998; 27: 325–34.
Aho K, Koskenvuo M, Tuominen J, Kaprio J. Occurrence of rheumatoid arthritis in a nationwide series of twins. J Rheumatol 1986; 13: 899–902.
Andersson EC, Svendsen P, Svejgaard A, Holmdahl R, Fugger L. A molecule basis for the HLA association in rheumatoid arthritis. Rev Immunogenet 2000; 2: 81–7.
Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24.
Boki KA, Panay GS, Vaughan RW, Drosos AA, Moutsopoulos HM, Lanchbury JS (1992) HLA class II sequence polymorphism and susceptibility to rheumatoid arthritis in Greeks: the HLA-DRß shared-epitope hyothesis accounts for the disease in only a minority of Greek patients. Arthritis Rheum 35: 749–755
Bologna C, Viu P, Jorgensen C, Sany J. Effect of age on the efficacy and tolerance of methotrexate in rheumatoid arthritis. Br J Rheumatol 1996; 35: 453–7.
Cimmino MA, Parisi M, Moggiana GL, Mela GS, Accardo S. The prevalence of rheumatoid arthritis in Italy: the Chiavari study. Ann Rheum Dis 1998; 57: 315–8.
Cimmino MA. Geographical differences in the prevalence and severity of rheumatoid arthritis in Europe. CPD Bull Rheumatol Arthritis 1999; 1: 28–34.
Del Puente A, Knowler WC, Pettitt DJ, Bennett PH. The incidence of rheumatoid arthritis is predicted by rheumatoid factor titer in a longitudinal population study. Arthritis Rheum 1988; 31: 1239–45.
Dequeker J. Rheumatic diseases in visual arts. General review. In: Appelboom T (ed.) Art, history and antiquity of rheumatic diseases. Elsevier, Brussels; 1987: 84.
Dugowson CE, Koepsell TD, Voigt LF, Bley L, Nelson JL, Dating JR. Rheumatoid arthritis in women: incidence rates in a group health cooperative, Seattle, Washington 1987–1989. Arthritis Rheum 1991; 34: 1502–7.
Ferraccioli GF, Salaffi F, Troise-Rioda W, Bartoli E. The chronic arthritis systemic index (CASI). Clin Exp Rheumatol 1994; 12: 241–7.
Garrod AB. The nature and treatment of gout and rheumatoid gout. London, Walton and Maberley; 1859.
Hameed K, Gibson T, Kadir M, Sultana S, Fatima Z, Syed A. The prevalence of rheumatoid arthritis in affluent and poor urban communities of Pakistan. Br J Rheumatol 1995; 34: 252–6.
Harris ED Jr. Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med 1990; 322: 1277–89.
Imanaka T, Shichikawa K, Inoue K, et al. Increase in age at onset of rheumatoid arthritis in Japan over a 30 year period. Ann Rheum Dis 1997; 56: 313–6.
Kaipiainen-Seppanen O, Aho K, Nikkarinen M. Regional differences in the incidence of rheumatoid arthritis in Finland in 1995. Ann Rheum Dis 2001; 60: 128–32.
Kaltenhauser S, Wagner U, Schuster E, et al. Immunogenetic markers and seropositivity predict radiological progression in early rheumatoid arthritis independent of disease activity. J Rheumatol 2001; 28: 735–44.
Kanik KS, Wilder RL. Hormonal alterations in rheumatoid arthritis, including the effects of pregnancy. Rheum Dis Clin North Am. 2000; 26: 805–23.
Kurumbail RG, Stevens AM, Gierse JK, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996; 384: 644–8.
Laan RF, van Riel PL, van De Putte LB. Leflunomide and methotrexate. Curr Opin Rheumatol 2001; 13: 159–63.
Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594–602.
O’Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996; 334: 1287–91.
Pasero G, Priolo P, Marubini E, et al. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum 1996; 39: 1006–15.
Rothschild BM, Woods RJ, Rothschild C, Sebes JI. Geographic distribution of rheumatoid arthritis in ancient North America: implications for pathogenesis. Semin Arthritis Rheum 1992; 22: 181–7.
Salvarani C, Macchioni PL, Mantovani W, et al. HLA-DRB1 alleles associated with rheumatoid arthritis in northern Italy: correlation with disease severity. Br J Rheumatol 1998; 37: 165–9.
Seriolo B, Accardo S, Fasciolo D, Bertolini S, Cutolo M. Lipoproteins, anticardiolipin antibodies and thrombotic events in rheumatoid arthritis. Clin Exp Rheumatol 1996; 14: 593–9.
Silman AJ, Davies P, Currey HLF, Evans SJW. Is rheumatoid arthritis becoming less severe? J Chron Dis 1983; 36: 891–7.
Silman AJ, 011ier WO, Holligan S, Birrel F, Adebajo A, Asuzu MC, Thomson W, Pepper L. Absence of rheumatoid arthritis in a rural Nigerian population. J Rheumatol 1993; 20: 618–22.
Symmons DPM, Barrett EM, Bankhead CR, Scott DGI, Silman AJ. The occurrence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. Br J Rheumatol 1994; 33: 735–9.
Van der Heijde DMFM, van Riel PLCM, van Rijswijk MH, et al. Influence of prognostic features on the final outcome in rheumatoid arthritis: a review of the literature. Semin Arthritis Rheum 1988; 17: 284–92.
Van der Hejde DMFM, van’t Hof MA, van Riel PLCM, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990; 49: 919–20.
Vittecoq O, Jouen-Beades F, Krzanowska K, et al. Rheumatoid factors, anti-filaggrin antibodies and low in vitro interleukin-2 and interferon-gamma production are useful immunological markers for early diagnosis of community cases of rheumatoid arthritis. A preliminary study. Joint Bone Spine. 2001; 68: 144–53.
Walsh DA, Pearson CI. Angiogenesis in the pathogenesis of inflammatory joint and lung diseases. Arthritis Res. 2001; 3: 147–53.
Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37: 481–94.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag Italia, Milano
About this chapter
Cite this chapter
Garlaschi, G., Silvestri, E., Satragno, L., Cimmino, M.A. (2002). History, Epidemiology and Clinical Evaluation of Rheumatoid Arthritis. In: The Rheumatoid Hand. Springer, Milano. https://doi.org/10.1007/978-88-470-2266-9_1
Download citation
DOI: https://doi.org/10.1007/978-88-470-2266-9_1
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-2268-3
Online ISBN: 978-88-470-2266-9
eBook Packages: Springer Book Archive